138 related articles for article (PubMed ID: 20219245)
1. Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.
Seker M; Ustaalioğlu BB; Bilici A; Yildirim ME; Kefeli U; Barisik NO; Tamer I; Gumus M
Leuk Res; 2010 Jul; 34(7):e160-3. PubMed ID: 20219245
[No Abstract] [Full Text] [Related]
2. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
3. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
Kyrtsonis MC; Siakantaris MP; Kalpadakis C; Dimopoulou MN; Vassilakopoulos TP; Kontopidou FN; Antoniou C; Korkolopoulou P; Panayiotidis P; Pangalis GA
Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
[TBL] [Abstract][Full Text] [Related]
4. Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab.
Park MY; Jung HJ; Park JE; Kim YC
Eur J Dermatol; 2010; 20(4):533-4. PubMed ID: 20542839
[No Abstract] [Full Text] [Related]
5. Remission of breakthrough hepatitis in chronic hepatitis B patients on lamivudine.
Koike K
J Gastroenterol; 2002; 37(11):988-90. PubMed ID: 12483259
[No Abstract] [Full Text] [Related]
6. Primary cutaneous marginal zone B-cell lymphoma: An atypical case.
Velázquez D; de Pablo P; García D; Ramírez JR
Dermatol Online J; 2010 Dec; 16(12):5. PubMed ID: 21199631
[TBL] [Abstract][Full Text] [Related]
7. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
Abasq C; Duval-Modeste AB; Courville P; Joly P
Ann Dermatol Venereol; 2008; 135(6-7):509-11. PubMed ID: 18598807
[No Abstract] [Full Text] [Related]
8. Rituximab as first line treatment for MALT lymphoma of extraocular muscles.
Benetatos L; Alymara V; Asproudis I; Bourantas KL
Ann Hematol; 2006 Sep; 85(9):625-6. PubMed ID: 16691396
[No Abstract] [Full Text] [Related]
9. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
10. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
Bonnekoh B; Schulz M; Franke I; Gollnick H
J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis.
Niscola P; Palumbo R; Scaramucci L; Tendas A; Cupelli L; Giovannini M; Piccioni D; Dentamaro T; Perrotti AP; de Fabritiis P
Cancer Chemother Pharmacol; 2009 Mar; 63(4):759-60. PubMed ID: 18500519
[No Abstract] [Full Text] [Related]
12. [A case of primary mucosa-associated lymphoid tissue lymphoma of the bladder regressed after rituximab in combination with CHOP chemotherapy].
Kakuta Y; Katoh T; Saitoh J; Yazawa K; Hosomi M; Itoh K
Hinyokika Kiyo; 2006 Dec; 52(12):951-4. PubMed ID: 17252980
[TBL] [Abstract][Full Text] [Related]
13. [Primary mucosa-associated lymphoid tissue lymphoma of the urinary bladder successfully treated by radiotherapy and rituximab].
Terasaki Y; Okumura H; Ishiura Y; Yokawa S; Kuribayashi M; Kodama K; Motoi I; Sugihara M; Saito K; Tanaka T; Yoshino T; Ohtake S; Nakao S
Rinsho Ketsueki; 2008 Jan; 49(1):30-4. PubMed ID: 18277593
[TBL] [Abstract][Full Text] [Related]
14. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection.
Marrone A; Zampino R; D'Onofrio M; Ricciotti R; Ruggiero G; Utili R
J Hepatol; 2004 Dec; 41(6):1064-5. PubMed ID: 15582146
[No Abstract] [Full Text] [Related]
15. Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab.
Nagasaka A; Matsue H; Kawamura T; Kanzaki M; Inozume T; Nakamura Y; Shimzu A; Shibagaki N; Yanagi M; Shimada S
J Dermatol; 2006 May; 33(5):377-9. PubMed ID: 16700675
[No Abstract] [Full Text] [Related]
16. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
17. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B.
Akarca US; Ersoz G; Gunsar F; Karasu Z; Saritas E; Yuce G; Batur Y
Antivir Ther; 2004 Jun; 9(3):325-34. PubMed ID: 15259895
[TBL] [Abstract][Full Text] [Related]
18. Successful rituximab monotherapy for API2-MALT1 fusion positive primary mucosa-associated lymphoid tissue lymphoma of the transverse colon in a patient with liver cirrhosis.
Yamada M; Kawahara H; Shiroeda H; Tsuchishima M; Masaki Y; Sato K; Takase S
Scand J Gastroenterol; 2008; 43(6):761-4. PubMed ID: 18569996
[No Abstract] [Full Text] [Related]
19. Regression of cirrhosis of the liver detected by elastiometry.
Mössner BK; Biagini M; Pedersen C; Christensen PB
Scand J Gastroenterol; 2008; 43(11):1401-2. PubMed ID: 18615357
[No Abstract] [Full Text] [Related]
20. Intravascular large B-cell lymphoma: successful therapy with bendamustine and rituximab.
Mleczko A; Franke I; Scheinpflug K; Gollnick H; Leverkus M
Acta Derm Venereol; 2009; 89(4):425-7. PubMed ID: 19688165
[No Abstract] [Full Text] [Related]
[Next] [New Search]
